Treg start-ups — who, what and how much: Data Byte

Among the newly emerging crop of venture-backed companies focused on immunosuppressive regulatory T cells, most are still disclosing few details about their platforms, making their fund-raisings, investors and founders the clearest differentiating markers in the landscape. Two Treg companies emerged from stealth this week, with the younger one revealing more details about its therapeutic strategy.

TRexBio, founded in 2018,  announced Tuesday the closing of a $59 million series A round and the appointment of Eli Lilly and Co. (NYSE:LLY) vet Johnston Erwin as CEO. ...